Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 2

15:17 EDT 21st September 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 26–50 of 7,800+

Probably Relevant

Nasdaq Stockholm AB: Observationsnoteringen för Wilson Therapeutics AB uppdateras / The observation status for Wilson Therapeutics AB is updated (89/18)

Den 11 april 2018 observationsnoterades aktierna i Wilson Therapeutics AB ("Bolaget") med hänvisning till ett offentligt uppköpserbjudande från Alexion Pharmaceuticals Inc., genom dess dotterbolag ...


Finch Therapeutics Names Ulrich Thienel Chief Medical Officer

Ulrich Theinel has been appointed chief medical officer of Finch Therapeutics. Before joining the Somerville, MA, microbiome therapeutics developer, Theinel held leadership positions at Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. Finch is currently in mid-stage clinical studies testing its microbial therapy as a treatment for Clostridium diffici...

Celsius Therapeutics Launches with $65M to Develop Precision Therapeutics for Autoimmune Disease & Cancer

Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer, launched with a $65 million Series A financing led by Third Rock Ventures with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and other key investors. Celsius is charting a new course of...


AdoRx raises $10m for new cancer therapeutics

UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.

Summit Therapeutics plc: Result of AGM

Summit Therapeutics plc ('Summit' or the 'Company')Result of Annual General MeetingOxford, UK, and Cambridge, MA, US, 7 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that...

4D Molecular Therapeutics Scores $90 Million in Series B Funding

4D Molecular Therapeutics snagged $90 million in a Series B financing round. The company intends to use the funds to advance its Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics.

Sandoz and Pear to create digital therapeutics for opioid use disorders

Novartis has signed an agreement with Pear Therapeutics to develop and commercialise prescription digital therapeutics for patients with substance and...Read More... The post Sandoz and Pear to create digital therapeutics for opioid use disorders appeared first on Pharmaceutical Technology.

Neon Therapeutics Announces Pricing of Initial Public Offerings

Neon Therapeutics (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. As quoted in the press release: In addition, Neon Therapeutics has granted the underwriters ...

M&As this week: United Therapeutics, Par Formulations, Endo Ventures

United Therapeutics Corporation has agreed to acquire SteadyMed for $216m. United Therapeutics will purchase SteadyMed for $4.46 a share in...Read More... The post M&As this week: United Therapeutics, Par Formulations, Endo Ventures appeared first on Pharmaceutical Technology.

SalvaRX sees 'substantial progress' as investees score patent protection

Drug development company SalvaRX Group offered a business update on Thursday, confirming significant progress for investees iOx Therapeutics and Intensity Therapeutics. iOsx Therapeutics, in which ...

Abeona Therapeutics Inc: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights

Investor Conference Call on Monday, May 14th at 10:00 am ET NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceuti...

Click Therapeutics Lands $17M to Advance Prescription Digital Therapeutics Platform

Click Therapeutics, Inc. (“Click”), a provider of Digital Therapeutics solutions as prescription medical treatments, has raised $17 million in funding led by Sanofi Ventures, the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sano...

Alexion Purchases Wilson Therapeutics for $855M: Expands Pipeline

Alexion Pharmaceuticals is buying Wilson Therapeutics for $855 million. With the company, Alexion will acquire WTX101, Wilson Therapeutics’ Phase III compound for Wilson disease.

Abeona Therapeutics Inc: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights

Investor Conference Call on Tuesday, March 27th at 10:00 am ET NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharma...

Shionogi Enters Into A License And Research Collaboration With Hsiri Therapeutics

NewsThe companies have entered into a license agreement regarding a collaborative licensing, research, and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

Centogene, Aldeyra to advance therapeutics for SLS patients

Centogene has signed an agreement with Aldeyra Therapeutics for the advancement of novel therapeutics for patients with Sjögren-Larsson Syndrome (SLS).

Rubius Therapeutics Looks to Raise $200 Million in IPO for Red-Cell Therapies

Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.

Spark Therapeutics, Inc.: Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia's "Best Places to Work" by the Philadelphia Business Journal

PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced t...

Spark Therapeutics, Inc.: Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias "besten Arbeitgeber" ausgezeichnet

PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...

M&As this week: PTC Therapeutics, Cambrex

PTC Therapeutics has signed an agreement to acquire Agilis Biotherapeutics for $945m. Agilis Biotherapeutics’ product pipeline includes four gene therapies programmes...Read More... The post M&As this week: PTC Therapeutics, Cambrex appeared first on Pharmaceutical Technology.

Evox raises £35m for exosome therapeutics

Oxford, UK-based Evox Therapeutics has raised £35 million to help advance its exosome-based therapeutics pipeline.

Q Therapeutics, REPROCELL Form MAGiQ Therapeutics

To treat demyelinating and degenerative diseases of the CNS

Nabriva Therapeutics Strengthens Antibiotics Leadership Position with Acquisition of Zavante Therapeutics

- Acquisition adds Zavante’s CONTEPO™, potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio - - Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 - - Ted Schroeder appointed as Nabriva’s CEO to continue Nabriva’s path to commercialization; Dr. Colin Broom to...

Sandoz targets digital therapeutics

Partners with Pear Therapeutics to launch FDA-approved apps

Abeona Therapeutics Inc: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease

NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene ther...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks